Nahdlatul Ulama

Achiko AG Announces Corporate Update Webcast

Retrieved on: 
Sunday, November 27, 2022
DNA, School, Nahdlatul Ulama, Hospital, Gold, University, COVID-19, Nanoparticle, CE marking, Union, Vaccine

AptameX is the Companys proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.

Key Points: 
  • AptameX is the Companys proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.
  • Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Achiko AG Announces Corporate Update Webcast

Retrieved on: 
Sunday, November 27, 2022
DNA, School, Nahdlatul Ulama, Hospital, Gold, University, COVID-19, Nanoparticle, CE marking, Union, Vaccine

AptameX is the Companys proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.

Key Points: 
  • AptameX is the Companys proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.
  • Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Achiko AG Announces Corporate Update Webcast

Retrieved on: 
Wednesday, November 16, 2022
DNA, School, Nahdlatul Ulama, Hospital, Gold, University, COVID-19, Nanoparticle, CE marking, Union, Vaccine

AptameX is the Companys proprietary saliva-based Covid-19 test utilizing DNA aptamers bound to gold nanoparticles in a colloidal solution.

Key Points: 
  • AptameX is the Companys proprietary saliva-based Covid-19 test utilizing DNA aptamers bound to gold nanoparticles in a colloidal solution.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.
  • Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Achiko AG Commences Commercial Deliveries in Indonesia

Retrieved on: 
Monday, November 14, 2022
Hospital, Marketing, ISIN, ACHI, CE marking, Nanoparticle, Aptamer, NU, Nahdlatul Ulama, Gold, COVID-19, Union, LR, OTCQB, School, University, Vaccine, DKI

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.
  • Were excited to commence commercial deliveries in Indonesia.
  • Achiko AG (SIX: ACHI.SW, OTCQB: ACHKF, www.achiko.com ) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.

Muslim World League: At first G20 Religious Forum (R20), Faith Leaders call for Global Alliance of Religious, Social & Political Leaders to tackle global crises

Retrieved on: 
Tuesday, November 8, 2022
Terrorism, Muslim World League, NU, Nahdlatul Ulama, Islam, General officer, Chaldean Catholic Church, Poverty, MWL, Intention, View, G20, Unemployment, Person, Pontifical council, Muslims, Solution, Religion, Archbishop, Multimedia, Wajahat Mirza, Renewable energy, R20

The first R20 was organisedby two of the world's largest Islamic non-governmental organisations, theMuslim World League (MWL)and the IndonesianNahdlatul Ulam (NU).

Key Points: 
  • The first R20 was organisedby two of the world's largest Islamic non-governmental organisations, theMuslim World League (MWL)and the IndonesianNahdlatul Ulam (NU).
  • The communique also called for, "religious and political leaders to join in building a global alliance founded upon shared civilizational values."
  • HE Muhammad Bin Abdulkarim Al-Issa also added: "Major global challenges today are not merely political or economic challenges.
  • It is time we acknowledge that religion and faith must be part of the solution for global political crises."

Achiko AG Production and Company Update

Retrieved on: 
Wednesday, November 2, 2022
Marketing, CEO, Nahdlatul Ulama, GLOBE, LR, Tourism, Health, COVID-19, LMIC, Government, ACHI, Education, Company, Union, First generation, Islam, CE marking, ISIN, Second generation, Pharmaceutical industry

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX Covid-19 test kit.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX Covid-19 test kit.
  • Were excited to pass this milestone, said Mr. Steven Goh, CEO of Achiko AG.
  • The contract is currently behind, however the Company expects to commence delivery as the Company enters the new year.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that put people first.

Achiko AG – Suspension of Trading

Retrieved on: 
Tuesday, June 28, 2022
Review, LR, School, GLOBE, COVID-19, ACHI, Company, SER, Annual report, ISIN, Mission statement, CE marking, Nahdlatul Ulama, Solution, Lawyer, Medical device, Issuer, Art

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) announces that it has received notification from SIX Exchange Regulation AG (SER) that the trading of Achikos shares shall be suspended as of Tuesday, June 28, 2022.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) announces that it has received notification from SIX Exchange Regulation AG (SER) that the trading of Achikos shares shall be suspended as of Tuesday, June 28, 2022.
  • Therefore, SER advised that the trading of Achikos shares shall be suspended based on Art.
  • Furthermore, SER has given Achiko AG a deadline until July 31, 2022, to publish audited financial statements in accordance with Art.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnosticsolutions that puts people first.

Achiko AG Announces Annual Results for the Year Ended December 31, 2021

Retrieved on: 
Monday, June 27, 2022
Review, Calibration, Annual report, OTCQB, Movement, USD, CEO, Capital, Authorised capital, Travel, Annual, GLOBE, COVID-19, General officer, ACHI, Union, Company, ISIN, Mass meeting, Technology, The Annual Report, Environment, CE marking, Organization, Optimism, Nahdlatul Ulama, Entrepreneurship, Annual general meeting, Chemistry, Frustration, Group, Animal, Audit, Pharmaceutical industry, Medical device, Health

ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (Achiko, the Company) announces its financial results for the year ended December 31, 2021, and progress since then.

Key Points: 
  • ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (Achiko, the Company) announces its financial results for the year ended December 31, 2021, and progress since then.
  • For the year ended December 31, 2021, the Group recorded a net loss of USD $9,231,779 resulting in an increase of the Groups accumulated losses to USD $34,568,395.
  • 2021 was a challenging year, said Mr. Steven Goh, Co-Founder and CEO of Achiko.
  • Achiko AG (OTCQB: ACHKF; SIX: ACHI.SW) ( www.achiko.com ) developing disruptive diagnostic solutions that puts people first.

Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 20, 2022

Retrieved on: 
Saturday, June 11, 2022
Mission statement, Company, CET, Listing Rules, Ë, Nahdlatul Ulama, COVID-19, Director, EBITDA, Annual report, Para, Contract, Islam, Record, EBIT, DAH, CE marking, Reproduction, Board, SER, Foreign exchange regulation, LR, USD, Bank, Cryptocurrency, Medical device, Issuer

Given the Companys position at year end, its focus was on commercializing AptameX.

Key Points: 
  • Given the Companys position at year end, its focus was on commercializing AptameX.
  • 53 LR in connection with the DAH) concerning this decision until Friday, June 10, 2022, 23.59 am CET, at the latest.
  • The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that puts people first.

Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021

Retrieved on: 
Thursday, May 19, 2022
ACHI, COVID-19, Company, EBITDA, CE marking, ISIN, Annual report, Mass meeting, AGM, USD, Marketing, LR, Union, Annual general meeting, Sale, Nahdlatul Ulama, CEO, GLOBE, Animal, Medical device

Full year unaudited adjusted EBITDA loss of USD$5,272,179 (2020: USD$8,728,709 loss) following 6 months unaudited loss of USD$3,915,136 to June30, 2021 and closing Shareholders Equity of USD ($4,297,969) (2020: USD$4,052,073).

Key Points: 
  • Full year unaudited adjusted EBITDA loss of USD$5,272,179 (2020: USD$8,728,709 loss) following 6 months unaudited loss of USD$3,915,136 to June30, 2021 and closing Shareholders Equity of USD ($4,297,969) (2020: USD$4,052,073).
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is pleased to report ahead of audited accounts to be presented later this month, the key unaudited financial results for the Company for the period ending December 31, 2021.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that puts people first.
  • Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.